VAY736
Phase 2/3Completed 1 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autoimmune Hepatitis
Conditions
Autoimmune Hepatitis
Trial Timeline
Feb 15, 2018 → Dec 17, 2025
NCT ID
NCT03217422About VAY736
VAY736 is a phase 2/3 stage product being developed by Novartis for Autoimmune Hepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT03217422. Target conditions include Autoimmune Hepatitis.
What happened to similar drugs?
0 of 13 similar drugs in Autoimmune Hepatitis were approved
Approved (0) Terminated (3) Active (10)
Hype Score Breakdown
Clinical
15
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05349214 | Phase 3 | Active |
| NCT05350072 | Phase 3 | Active |
| NCT03217422 | Phase 2/3 | Completed |
| NCT02962895 | Phase 2 | Completed |
| NCT02137889 | Phase 1 | Terminated |
Competing Products
20 competing products in Autoimmune Hepatitis